Kisspeptin
Kisspeptin-10 / KISS1-derived reproductive neuropeptide
Reproductive peptide research focused on GnRH signaling and regulation of the hypothalamic-pituitary-gonadal axis.
Route
Subcutaneous in many human studies and the community protocol
Common format
10 mg vial
Research focus
GnRH/LH/FSH signaling
Evidence level
Limited Human Evidence
Typical cycle
8–12 weeks
HormonalKisspeptin in 30 seconds
Atlas Fast ReadWhat it is
Kisspeptin-10 / KISS1-derived reproductive neuropeptide
Why people care
Reproductive peptide research focused on GnRH signaling and regulation of the hypothalamic-pituitary-gonadal axis.
Human evidence
Limited Human Evidence — Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.
Biggest misconception
Key gaps include larger independent trials, clearer dose-response data, long-term safety, clinically meaningful endpoints, and evidence that findings generalize beyond the narrow populations or routes already studied.
Bottom line
Kisspeptin has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims.
Overview
What is Kisspeptin?
Kisspeptin is kisspeptin-10 / KISS1-derived reproductive neuropeptide. Reproductive peptide research focused on GnRH signaling and regulation of the hypothalamic-pituitary-gonadal axis.
The KISS1 gene was identified in 1996 as a metastasis-suppressor gene; its peptide products were later shown in the early 2000s to be critical upstream regulators of GnRH and puberty. Human reproductive-endocrinology studies followed.
Mechanism
How it works
Activates KISS1R/GPR54 on hypothalamic GnRH neurons, increasing GnRH release and downstream LH/FSH secretion. This makes it an upstream regulator of reproductive endocrine signaling.
Research areas
Evidence
What does the evidence actually say?
Human interventional or clinical data exist, but studies are small, early-phase, mixed, indirect, route-specific, or not confirmatory.
Preclinical Evidence
Limited Human Evidence
Strong Human Evidence
Human evidence
Preclinical evidence
Knowledge gaps
Protocol
Research protocol
Dose
Frequency
Timing
Route
Cycle length
Reconstitution
Storage
Monitoring
Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.
Safety
Safety, side effects, and precautions
Side effects
Contraindications
Interactions
Stacks
Common stacks
No well-supported stack is highlighted for this peptide yet.
Questions
FAQ
References
Sources
Atlas
The Atlas verdict
Kisspeptin has a real human signal or documented human pharmacology, but evidence is too small, mixed, route-specific, or indication-specific to justify broad claims. The most defensible use of the literature is to separate what has actually been measured in people from what is still extrapolated from mechanism or animal work.